MedPath

SE OF DEXMEDETOMIDINE AND BENZODIAZEPINES IN SEVERE ALCOHOL WITHDRAWAL FOR SEDATIO

Phase 4
Conditions
Health Condition 1: F101- Alcohol abuse
Registration Number
CTRI/2024/04/065482
Lead Sponsor
Pradeep S
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients with severe alcohol withdrawal(F10.231) as defined BY ICD-10 guidelines

Exclusion Criteria

Patient under 18 years of age,pregnant women,patients with limited life expectancy due to chronic diseases,patients with pre existing neurological illness,Concomitant Substance abuse

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare differences in Median Benzodiazepine Dose in the First 24-hour among two study groups for maintaining light to moderate sedation with target RASS score of 0 to -2.Timepoint: 24 hours
Secondary Outcome Measures
NameTimeMethod
ength of ICU stay, sedation quality, The ability to communicate, Haloperidol requirements, CIWA-Ar Score during admission and after 24 hours between two groupsTimepoint: Throughout ICU/ED Admission
© Copyright 2025. All Rights Reserved by MedPath